Buspirone in the Management of Anxiety and Irritability in Children With Pervasive Developmental Disorders: Results of an Open-Label Study
J Clin Psychiatry 1998;59:56-59
© Copyright 2014 Physicians Postgraduate Press, Inc.
Purchase This PDF for $40.00
If you are not a paid subscriber, you may purchase the PDF.
(You'll need the free Adobe Acrobat Reader.)
Receive immediate full-text access to JCP. You can subscribe to JCP online-only ($86) or print + online ($156 individual).
With your subscription, receive a free PDF collection of the NCDEU Festschrift articles. Hurry! This offer ends December 31, 2011.
If you are a paid subscriber to JCP and do not yet have a username and password, activate your subscription now.
As a paid subscriber who has activated your subscription, you have access to the HTML and PDF versions of this item.
Click here to login.
Did you forget your password?
Still can't log in? Contact the Circulation Department at 1-800-489-1001 x4 or send email
Background: We evaluated the efficacy and safety
of buspirone in the management of anxiety and irritability in
children with pervasive developmental disorders (PDD).
Method: Twenty-two subjects, 6 to 17 years old,
with DSM-III-R diagnosed PDD-NOS (N=20) or autistic disorder
(N=2), were included. They were treated with buspirone in dosages
ranging from 15 to 45 mg/day in an open-label trial lasting 6 to
8 weeks. Responders continued buspirone treatment and were
followed up for up to 12 months.
Results: Nine subjects had a marked therapeutic
response and 7 subjects a moderate response on the Clinical
Global Impressions (CGI) scale after 6 to 8 weeks of treatment.
Side effects were minimal, except for 1 patient who developed
abnormal involuntary movements.
Conclusion: These results suggest that buspirone
may be useful for treating symptoms of anxiety and irritability
in children with PDD.